ANNEE 2015

Publié le 31/03/2016 à 15h00 (mis à jour le 14/04/2016 à 14h51)

PHARMACOLOGIE FONDAMENTALE

Bellot M, Galandrin S, Boularan C, Matthies HJ, Despas F, Denis C, Javitch J, Mazères S, Sanni SJ, Pons V, Seguelas MH, Hansen JL, Pathak A, Galli A, Sénard JM, Galés C. Dual agonist occupancy of AT1-R-α2C-AR heterodimers results in atypical Gs-PKA signaling. Nat Chem Biol. 2015 ;11:271-9.

PHARMACOLOGIE CLINIQUE

Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, Schmid M, Singh P, Tolosa E, Chaudhuri KR. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015 ;22:1400-7.

Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-Pecurariu C, Kessel B, Silverdale M, Todorova A, Sauerbier A, Odin P, Antonini A, Martinez-Martin P ; EUROPAR and the IPMDS Non Motor PD Study Group. King’s Parkinson’s disease pain scale, the first scale for pain in PD : An international validation. Mov Disord. 2015 ;30:1623-31.

Dhainaut JF, Diebolt V, Pouletty-Lefèbvre B ; the participants of round table N°6 at Giens XXX :, Baker A, Bassompierre F, Borel T, Braunstein D, Demotes J, François B, Huet S, Micallef J, Misse C, Molon A, Rascol O, Ravoire S, Schwartz B, Donne N, Donne N, Fusaï G, Pouletty P, Vicaut E. What Strategy Should France Implement for H2020 ? Therapie. 2015 ;70:103-109.

Dhainaut JF, Diebolt V, Pouletty-Lefèbvre B ; les participants à la table ronde N°6 de Giens XXX :, Baker A, Bassompierre F, Borel T, Braunstein D, Demotes J, François B, Huet S, Micallef J, Misse C, Molon A, Rascol O, Ravoire S, Schwartz B, Donne N, Fusaï G, Pouletty P, Vicaut E. Quelle stratégie française dans le cadre H2020 ? Therapie. 2015 ;70:95-102.

Fuzier R, Rousset J, Bataille B, Salces-y-Nédéo A, Maguès JP. One half of patients reports persistent pain three months after orthopaedic surgery. Anaesth Crit Care Pain Med. 2015 ;34:159-64.

Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease : Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol. 2015 ;72:1491-500.

Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, Lüscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, Wijns W, Zeller T, Schmieder RE. Proceedings from the European clinical consensus conference for renal denervation : considerations on future clinical trial design. Eur Heart J. 2015 ;36:2219-27.

Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D ; Parkgait-II Study Group. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. Brain. 2015 ;138:1271-83.

Morgan DA, Despas F, Rahmouni K. Effects of leptin on sympathetic nerve activity in conscious mice. Physiol Rep. 2015 ;3. pii : e12554.

Nemmi F, Sabatini U, Rascol O, Péran P. Parkinson’s disease and local atrophy in subcortical nuclei : insight from shape analysis. Neurobiology of Aging. 2015 ;36:424-33.

Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W ; National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease : Consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015 ;21:1133-44.

Paris A, Deygas B, Cornu C, Thalamas C, Maison P, Duale C, Kane M, Hodaj E, Cracowski JL. Improved informed consent documents for biomedical research do not increase patients’ understanding but reduce enrolment : a study in real settings. Br J Clin Pharmacol. 2015 ;80:1010-20.

Pathak A, Coleman L, Roth A, Stanley J, Bailey L, Markham P, Ewen S, Morel C, Despas F, Honton B, Senard JM, Fajadet J, Mahfoud F. Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity. Euro Intervention. 2015 ;11:477-84.

Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O ; for the Rasagiline-for-MSA investigators. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy : a randomised, placebo-controlled trial. Lancet Neurol. 2015 ;14:145-52.

Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson’s Disease-Associated Chronic Pain. J Clin Pharmacol. 2015 ;doi : 10.1002/jcph.678.

Rascol O, Perez-Lloret S, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Negre-Pages L.Falls in ambulatory non-demented patients with Parkinson’s disease. J Neural Transm (Vienna). 2015 ;122:1447-55.

Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord. 2015 ;30:1451-60.

Ratti PL, Sierra-Peña M, Manni R, Simonetta-Moreau M, Bastin J, Mace H, Rascol O, David O. Distinctive features of NREM parasomnia behaviors in parkinson’s disease and multiple system atrophy. PLoS One. 2015 ;10:e0120973.

Ratti PL, Nègre-Pagès L, Pérez-Lloret S, Manni R, Damier P, Tison F, Destée A, Rascol O. Subjective sleep dysfunction and insomnia symptoms in Parkinson’s disease : Insights from a cross-sectional evaluation of the French CoPark cohort. Parkinsonism Relat Disord. 2015 ;21:1323-9.

Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M, Ardouin C, Chéreau I, Brefel-Courbon C, Ory-Magne F, Klinger H, Peyrol F, Schupbach M, Dujardin K, Tison F, Houeto JL, Krack P, Durif F. International validation of a behavioral scale in Parkinson’s disease without dementia. Mov Disord. 2015 ;30:705-13.

Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M ; PANDA study group. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA) : a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015 ;14:1161-70.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin Syndrome : Analysis of Cases Registered in the French Pharmacovigilance Database. J Clin Psychophar. 2015 ;35:382-8.

Abadie D, Hurault-Delarue C, Damase-Michel C, Montastruc JL, Lacroix I. Medication exposure and spontaneous abortion : a case-control study using a French medical database. Clin Exp Obstet Gynecol. 2015 ;42:431-6.

Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. J Am Med Dir Assoc. 2015 ;16:898.e1-7.

Bénard-Laribière A, Miremont-Salamé G, Pérault-Pochat MC, Noize P, Haramburu F ; EMIR Study Group on behalf of the French network of pharmacovigilance centres. Incidence of hospital admissions due to adverse drug reactions in France : the EMIR study. Fundam Clin Pharmacol. 2015 ;29:106-11.

Bernard N, Jantzem H, Becker M, Pecriaux C, Bénard-Laribière A, Montastruc JL, Descotes J, Vial T ; French Network of Regional Pharmacovigilance Centres. Severe adverse effects of bromocriptine in lactation inhibition : a pharmacovigilance survey. BJOG. 2015 ;122:1244-51.

Berreni A, Montastruc F, Bondon-Guitton E, Rousseau V, Abadie D, Durrieu G, Chebane L, Giroud JP, Bagheri H, Montastruc JL. Adverse drug reactions to self-medication : a study in a pharmacovigilance database. Fundam Clin Pharmacol. 2015 Jul 28. doi : 10.1111/fcp.12140.

Borel C, Lamy S, Compaci G, Récher C, Jeanneau P, Nogaro JC, Bauvin E, Despas F, Delpierre C, Laurent G. A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma : implication for survival. BMC Cancer. 2015 ;15:288.

Brefel-Courbon C. Médicament et cognition chez le sujet âgé. Therapie. 2015 ;70:523-26.

Cailhol L, Thalamas C, Garrido C, Birmes P, Lapeyre-Mestre M. Mental health service utilization among borderline personality disorder patients inpatient. Encephale. 2015 ;41:115-122.

Caillet C, Sichanh C, Syhakhang L, Delpierre C, Manithip C, Mayxay M, Lapeyre-Mestre M, Newton PN, Roussin A. Population awareness of risks related to medicinal product use in Vientiane Capital, Lao PDR : a cross-sectional study for public health improvement in low and middle income countries. BMC. 2015 ;15:590.

Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy PA, Favre J, Simon N, Bordet R, Rolland B. Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals : A Systematic Review of Recent Prescription Trends. Curr Pharm Des. 2015 ;21:3280-97.

Chayé H, Bernard M, Tubéry M, Rousseau V, Ecoiffier M, Montastruc JL, Bagheri H. Hospital readmission induced by adverse drug reaction : A pilot study in a post-emergency unit of a French university hospital. Rev Med Interne. 2015 ;36:450-6.

Chebane L, Bagheri H, Hillaire-Buys D, Géniaux H, Yahioui N, Laroche ML, Cottin J, Spreux A, Mosquet B, Pecriaux C, Bellet F, Lambert A, Montastruc JL. Pancréatites d’origine médicamenteuse. Revue des notifications spontanées en France. Drug-induced pancreatitis. A review of French spontaneous reports. La Revue de médecine interne. 2015 ;36:573-78.

Compaci G, Rueter M, Lamy S, Oberic L, Recher C, Lapeyre-Mestre M, Laurent G, Despas F. Ambulatory Medical Assistance - After Cancer (AMA-AC) : A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy. BMC Cancer. 2015 ;15:781.

Courrier V, Fournier JP, Sommet A, Montastruc JL, Poutrain JC. Parenteral anticoagulants use in general practice : a cross-sectional study in south western France. Clin Appl Thromb Hemost. 2015 ;21:319-24.

Damase-Michel C. Médicament et grossesse. Traiter une femme enceinte : un choix raisonné. Act pharmaceutique. 2015 ;550:15.

de Souto Barreto P, Demougeot L, Pillard F, Lapeyre-Mestre M, Rolland Y. Exercise training for managing behavioral and psychological symptoms in people with dementia : A systematic review and meta-analysis. Ageing Res Rev. 2015 ;24:274-85.

Diot C, Eiden C, Roussin A, Batisse A, Boucher A, Chavant F, Daveluy A, Donadieu-Rigole H, Peyrière H ; et le réseau des centres français d’addictovigilance. Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene : unrecognized interaction. Eur J Clin Pharmacol. 2015 ;71:1539-40.

Egron A, Olivier-Abbal P, Gouraud A, Babai S, Combret S, Montastruc JL, Bondon-Guitton E. Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports. Targ Oncol. 2015 ;10:229-34.

Faillie JL. Indication bias or protopathic bias ? Br J Clin Pharmacol. 2015 ;80:779-80.

Faillie JL, Suissa S. Immortal Time Bias in Pharmacoepidemiological Studies : Definition, Solutions and Examples. Thérapie. 2015 ;70:259-63.

Faillie JL, Filion KB, Patenaude V, Ernst P, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. Diabetes Obes Metab. 2015 ;17:379-85.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P ; Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations : a randomised, double-blind, controlled trial. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations : a randomised, double-blind, controlled trial. Lancet Neurol. 2015 ;15:154-165.

Fournier JP, Yin H, Nessim SJ, Montastruc JL, Azoulay. Tramadol for non-cancer pain and the risk of hyponatremia. Am J Med. 2015 ;128:418-425.

Fournier JP, Azoulay L, Yin H, Montastruc JL, Suissa S. Tramadol Use and the Risk of Hospitalization for Hypoglycemia in Patients With Noncancer Pain. JAMA Intern Med. 2015 ;175:186-93.

Fuzier R. Yet more on Pecs block nomenclature. Anaesthesia. 2015 ;70:508-509.

Fuzier R, Casalprim J, Bataille B, Harper I, Magues JP. The echogenicity of nerve blockade needles. Anaesthesia. 2015 ;70:462-466.

Fuzier R. Problématique de l’anesthésie locorégionale dans l’obésité. Regional anaesthesia in obese patient. Obésité. 2015 ;10:227-231.

Gallini A, Gardette V, Lapeyre-Mestre M, de Souto Barreto P, Vellas B, Andrieu S, Rolland Y. Dementia Diagnosis and Influenza Vaccination in French Nursing Home Residents. J Am Geriatr Soc. 2015 ;63:1256-8.

Girault D, Trouvin JH, Blachier-Poisson C, Gary F, Laloye D ; participants of round table N°3 of Giens XXX :, Bergmann JF, Casadevall N, Delval C, De Sahb Berkovitch R, Fagon JY, Gersberg M, Lassale C, Lechat P, Le Jeunne C, Montastruc JL, Prugnaud JL, Ratignier-Carbonneil C, Rey-Coquais C. Biosimilars : from Technical to Pharmacoeconomic Considerations. Thérapie. 2015 ;70:47-55.

Girault D, Trouvin JH, Blachier-Poisson C, Gary F, Laloy D ; les participants à la table ronde N°3 de Giens XXX : Bergmann JF, Casadevall N, Delval C, Berkovitch Rde S, Fagon JY, Gersberg M, Lassale C, Lechat P, Le Jeunne C, Montastruc JL, Prugnaud JL, Ratignier-Carbonneil C, Rey-Coquais C. Biosimilaires : de la technique au médicoéconomique. Thérapie. 2015 ;70:37-46.

Guiraud T, Labrunée M, Pillard F, Granger R, Bousquet M, Richard L, Boned A, Pathak A, Gayda M, Gremeaux V. Whole-Body Strength Training Using a Huber Motion Lab in Coronary Heart Disease Patients : Safety, Tolerance, Fuel Selection, and Energy Expenditure Aspects and Optimization. Am J Phys Med Rehabil. 2015 ;94:385-94.

Jacomet C, Allavena C, Peyrol F, Pereira B, Joubert LM, Bagheri H, Cotte L, Garaffo R, Gerbaud L, Dellamonica P. Perception of Antiretroviral Generic Medicines : One-Day Survey of HIV-Infected Patients and Their Physicians in France. PLoS One. 2015 ;10:e0117214.

Jouanjus E, Gibaja V, Kahn JP, Haramburu F, Daveluy A. Signal identification in addictovigilance : the functioning of the French system.Thérapie. 2015 ;70:123-31.

Jouanjus E, Gibaja V, Kahn JP, Haramburu F, Daveluy A. Comment identifier un signal en addictovigilance ? Therapie. 2015 ;70:113-22.

Labrunée M, Boned A, Granger R, Bousquet M, Jordan C, Richard L, Garrigues D, Gremeaux V, Sénard JM, Pathak A, Guiraud T. Improved Walking Claudication Distance with Transcutaneous Electrical Nerve Stimulation : An Old Treatment with a New Indication in Patients with Peripheral Artery Disease. Am J Phys Med Rehabil. 2015 ;94:941-9.

Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. Eur Ann Otorhinolaryngol Head Neck Dis. 2015 ;132:31-4.

Laconi S, Cailhol L, Pourcel L, Thalamas C, Lapeyre-Mestre M, Chabrol H. Relationship between defense mechanism and therapeutic alliance. Encephale. 2015 ;41:429-34.

Laffon de Mazières C, Lapeyre-Mestre M, Vellas B, de Souto Barreto P, Rolland Y. Organizational Factors Associated With Inappropriate Neuroleptic Drug Prescribing in Nursing Homes : A Multilevel Approach. J Am Med Dir Assoc. 2015 ;16:590-7.

Laffont MA, Michaud M, Pugnet G, Gigaud M, Arlet P, Sailler L, Astudillo L. Lower limb pain of unusual cause. Rev Med Interne. 2015 ;36:566-67.

Lapeyre-Mestre M, Dupui M. Drug abuse monitoring : which pharmacoepidemiological resources at the European level ? Thérapie. 2015 ;70:157-65.

Lapeyre-Mestre M, Dupui M. Système de surveillance en addictovigilance : quelles données pharmacoépidémiologiques à l’échelle de l’Europe ? Thérapie. 2015 ;70:147-56.

Lacroix I. Médicaments et allaitement. Duel effets pour bébé ? Science et santé. 2015 ;23:36.

Le Querrec F, Bounes V, Mestre ML, Azema O, Longeaux N, Gallart JC. Regional Observatory of Emergency Medicine in Midi-Pyrénées-France (ORU-MiP). Sex and age differences in ED patients with mental and behavioral disorders due to psychoactive substance use. Am J Emerg Med. 2015 ;33:1612-16.

Linselle M, Montastruc F, Jantzen H, Valnet-Rabier MB, Haramburu F, Coquerel A, Gouraud A, Perault-Pochat MC, Bagheri H, Montastruc JL. Drugs and Sleep Apneas ? A review of the French Pharmacovigilance database.Therapie. 2015 ;70:347-50.

Meyrignac O, Moreno R, Baunin C, Vial J, Accadbled F, Sommet A, de Gauzy JS. Low-dose biplanar radiography can be used in children and adolescents to accurately assess femoral and tibial torsion and greatly reduce irradiation. Eur Radiol. 2015 ;25:1752-60.

Micallef J, Frauger E, Palmaro A, Boucherie Q, Lapeyre Mestre M. Example of an investigation of an "emergent" phenomenon in addiction vigilance : the case of methylphenidate.Thérapie. 2015 ;70:197-202.

Micallef J, Frauger E, Palmaro A, Boucherie Q, Lapeyre Mestre M. Un exemple d’investigation d’un phénomène « émergent » en addictovigilance : à propos du méthylphénidate. Thérapie. 2015 ;70:191-6.

Micallef J, Lapeyre-Mestre M.  Addictovigilance : le défi pharmacologique de l’évaluation et de la prévention des substances à risque. Thérapie. 2015 ;70:111.

Michaud M, Moulis G, Balardy L, Pourrat J, Huart A, Gaches F, Cougoul P, Blancher A, Puissant B, Arlet P, Sailler L. Cryofibrinogenemia : A single-center study at the University Hospital of Toulouse. Rev Med Interne. 2015 ;36:237-42.

Michaud M, Moulis G, Puissant B, Balardy L, Huart A, Gaches F, Cougoul P, Arlet P, Blancher A, Pourrat J, Sailler L. Cryofibrinogenemia : a marker of severity of cryoglobulinemia vasculitis. Am J Med. 2015 ;8:916-21.

Montastruc F, Rieu J, Letamendia C, Montastruc JL, Pathak A, Schmitt L. Measurement of QT interval and serotoninergic reuptake inhibitor antidepressants : a study in a university psychiatric hospital. L’Encéphale. 2015 ;41:282-283.

Montastruc F, Rouanet S, Gardette V, Rousseau V, Bagheri H, Montastruc JL. Atropinic burden of prescriptions forms in patients with Alzheimer disease : a cross-sectional study in a French PharmacoVigilance Database. Eur J Clin Pharmacol. 2015 ;71:891-5.

Montastruc F. VigiBIP, un nouvel outil pour le bon usage du médicament. Trait d’Union. 2015 ;144:7.

Montastruc F, Palmaro A, Bagheri H, Schmitt L, Montastruc JL, Lapeyre-Mestre M. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes : A pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol. 2015 ;25:1556-65.

Montastruc JL, Bagheri H, Montastruc F. Antivitamines K. la maladie thrombo-embolique veineuse, 1 volume, Elsevier Masson SAS. Ph Lacroix. 2015 ;27:243-248.

Montastruc JL, Queneau P. Sur la demande d’avis relatifs à l’autorisation pour la communauté urbaine du Grand Nancy d’exploiter une eau minérale naturelle pour l’alimentation en eaux d’un centre thermal au titre de l’article L 1322-1du code de la santé publique. Rapport 14-04. Bull Acad Natle Méd. 2014 ;198:859-65.

Montastruc JL, Rousseau V, Chebane L, Abadie D, Bondon-Guitton E, Durrieu G, Montastruc F, Bagheri H. Hemorrhagic effects of oral anticoagulants : a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA). Eur J Clin Pharmacol. 2015 ;71:1283-84.

Moulis F, Moulis G, Balardy L, Gérard S, Sourdet S, Rougé-Bugat M, Lapeyre-Mestre M, Montastruc JL, Rolland Y, Vellas B. Searching for a Polypharmacy Threshold Associated With Frailty. J Am Med Dir Assoc. 2015 ;16:259-61.

Moulis F, Moulis G, Balardy L, Gérard S, Montastruc F, Sourdet S, Rougé-Bugat M, Lapeyre-Mestre M, Montastruc J, Rolland Y, Vellas B. Exposure to Atropinic Drugs and Frailty Status. J Am Med Dir Assoc. 2015 ;16:253-7.

Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol. 2015 ;90:301-5.

Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L. French health insurance databases : What interest for medical research ? Rev Med Interne. 2015 ;36:411-17.

Moulis G, Sailler L, Lapeyre-Mestre M.  Severe bleeding events in adults and children with primary immune thrombocytopenia : a systematic review : comment. J Thromb Haemost. 2015 ;13:1521-31.

Moulis G, Lapeyre-Mestre M, Montastruc JL, Sailler L. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Autoimmunity Reviews. 2015 ;14:168-73.

Moulis G, Palmaro A, Sailler L, Lapeyre-Mestre M. Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study. PLoS One. 2015 ;10:e0142217.

Nguyen TTL, Palmaro A, Montastruc F, Lapeyre-Mestre M, Moulis G. Signal for Thrombosis with Eltrombopag and Romiplostim : A Disproportionality Analysis of Spontaneous Reports Within VigiBase®. Drug Saf. 2015 ;38:1179-86.

Palmaro A, Bissuel R, Renaud N, Durrieu G, Escourrou B, Oustric S, Montastruc JL, Lapeyre-Mestre M. Off-label prescribing in pediatric outpatients. Pediatrics. 2015 ;135:49-58.

Palmaro A, Dupouy J, Lapeyre-Mestre M. Benzodiazepines and risk of death : Results from two large cohort studies in France and UK. Eur Neuropsychopharmacol. 2015 ;25:1566-77.

Pauly V, Lapeyre-Mestre M, Braunstein D, Rueter M, Thirion X, Jouanjus E, Micallef J. Detection of signals of abuse and dependence applying disproportionality analysis. Eur J Clin Pharmacol. 2015 ;71:229-36.

Pugnet G, Sailler L, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Is Statin Exposure Associated with Occurrence or Better Outcome in Giant Cell Arteritis ? Results from a French Population-based Study. J Rheumatol. 2015 ;42:316-22.

Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list : a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015:1860-9.

Rouge-Bugat ME, Lassoued D, Bacrie J, Boussier N, Delord JP, Oustric S, Bauvin E, Lapeyre-Mestre M, Bertucci F, Grosclaude P. Guideline sheets on the side effects of anticancer drugs are useful for general practitioners. Support Care Cancer. 2015 ;23:3473-80.

Roulet L, Ballereau F, Lapeyre-Mestre M, Joris-Frasseren M, Asseray N. Developing a Terminology in the French Language for Clinical Practice and Research in Drug Safety. Thérapie. 2015 ;70:283-92.

Roussin A, Doazan-d’Ouince O, Géniaux H, Halberer C ; French Network of Centre for Evaluation and Information on Pharmacodependence (Addictovigilance Centres). Evaluation of abuse and dependence in addiction monitoring systems : tramadol as an example. Thérapie. 2015 ;70:213-21.

Roussin A, d’Ouince OD, Géniaux H, Halberer C ; réseau français des Centres d’Évaluation et d’Information sur la Pharmacodépendance (Centres d’Addictovigilance). Un exemple d’évaluation de l’abus et de la dépendance en addictovigilance : à propos du tramadol. Thérapie. 2015 ;70:203-11.

Saliba L, Mondoly P, Duparc A, Bura-Rivière A, Maury P, Calmels V, Sallerin B, Pathak A, Montastruc JL, Bagheri H. Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation. Thérapie. 2015 ;70:485-92.

Sattler V, Acket B, Raposo N, Albucher JF, Thalamas C, Loubinoux I, Chollet F, Simonetta-Moreau M. Anodal tDCS Combined With Radial Nerve Stimulation Promotes Hand Motor Recovery in the Acute Phase After Ischemic Stroke. Neurorehabil Neural Repair. 2015 ;29:743-54.

Sénard JM.  Prise en charge de l’hypotension orthostatique. Cardiologiques. 2015 ;309:1-4.

Terrier B, Dechartres A, Girard C, Jouneau S, Kahn JE, Dhote R, Lazaro E, Cabane J, Papo T, Schleinitz N, Cohen P, Begon E, Belenotti P, Chauveau D, Diot E, Généreau T, Hamidou M, Hayem G, Le Guenno G, Le Guern V, Michel M, Moulis G, Puéchal X, Rivière S, Samson M, Gonin F, Le Jeunne C, Corlieu P, Mouthon L, Guillevin L ; French Vasculitis Study Group. Granulomatosis with polyangiitis : endoscopic management of tracheobronchial stenosis : results from a multicentre experience. Rheumatology. 2015 ;54:1852-57.

Thorel J, Civade E, Quintyn JC, Cestac P, Montastruc JL, Bagheri H. Ischaemic stroke after exposure to aflibercept : interaction with vitamin K antagonist and/or direct pharmacodynamic effect ? J Clin Pharm Ther. 2015 ;40:477-79

Tillement JP, Hauw JJ, Papadopoulos V, Montastruc JL. Vieillissement et démences : un défi médical, scientifique et socio-économique. Thérapie. 2015 ;70:239.

Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D ; French Behçet Network. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease : Multicenter study of 124 patients. J Autoimmun. 2015 ;62:67-74.